<DOC>
	<DOC>NCT00562484</DOC>
	<brief_summary>This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe complications following influenza infection.</brief_summary>
	<brief_title>A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy males and females aged ≥ 18 to &lt; 65 years at the time of vaccination Non pregnant/ non lactating females Hypersensitivity to influenza vaccine or allergy to any components of the Study Vaccines Vaccination against influenza in the previous 6 months Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality Known history of GuillainBarré Syndrome; Clinical signs of active infection and/or an oral temperature of ≥ 37.8 oC. History of neurological disorders or seizures Confirmed or suspected immunosuppressive condition or a previously diagnosed immunodeficiency disorder Current or recent immunosuppressive or immunomodulative therapy, including systemic corticosteroids Administration of immunoglobulins and/or any blood products; Participation in a clinical trial or use of an investigational compound; Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior; Participants indicated to receive an influenza vaccine on an annual basis according to the local public health recommendations.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>